| Literature DB >> 25838173 |
Xue-Jiao Zhang1,2,3, Wen-Li Mei4, Guang-Hong Tan5, Cai-Chun Wang6, Song-Lin Zhou7, Feng-Ru Huang8, Bin Chen9, Hao-Fu Dai10, Feng-Ying Huang11.
Abstract
Cardenolides with special chemical structures have been considered as effective anti-cancer drugs in clinic trials. Strophalloside is a cardenolide we recently isolated from Antiaris toxicaria obtained from Hainan, China. The aim of this study was to investigate the possible anticancer effects induced by strophalloside and the underlying molecular mechanism. Gastric carcinoma SGC-7901 cells were treated with strophalloside at various concentrations for different times, and resulting cell viability was determined by the MTT assay, and the motility and invasion of tumor cells were assessed by the Transwell chamber assay. Apoptosis were measured by Annexin V-FITC/PI and Hoechst staining. The changes of mitochondrial transmembrane potential were examined by a JC-1 kit. The expressions of pro-apoptotic protein cytochrome c, caspase-3 and caspase-9 were detected by western blotting analysis. The results showed that strophalloside was capable of reducing cell viability, inhibiting cell growth, and suppressing cell migration and invasion in a time- and dose-dependent manner. Mitochondrial membrane potential declined and the concentration of cytochrome c increased in cytoplasm and caspase-3 and caspase-9 were cleaved into activated states, suggesting that cytochrome c was released from the mitochondrion to cytoplasm and finally activated the caspase-dependent apoptosis pathway. Our results indicate that strophalloside is a potential anticancer drug.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25838173 PMCID: PMC6272525 DOI: 10.3390/molecules20045714
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(a) The structure of cardenolides and a summary of structural features regarding the observed anti-cancer cytotoxicity; (b) the structure of strophalloside.
Strophalloside inhibition of SGC-7901 cell proliferation.
| Groups | Dose (nM/mL) | 24 h | 48 h | ||
|---|---|---|---|---|---|
| A Value | Inhibition (%) | A Value | Inhibition (%) | ||
| Control | 0.0 | 0.92 ± 0.027 | 00.00 ± 00.00 | 0.975 ± 0.034 * | 00.00 ± 00.00 |
| Strophalloside | 0.12 | 0.855 ± 0.029 * | 7.06 ± 3.15 * | 0.890 ± 0.056 * | 8.71 ± 5.80 * |
| 0.24 | 0.782 ± 0.015 * | 15.00 ± 1.60 * | 0.747 ± 0.040 * | 23.38 ± 4.23 * | |
| 0.47 | 0.675 ± 0.009 * | 26.63 ± 1.02 * | 0.356 ± 0.012 * | 62.56 ± 1.31 * | |
| 0.93 | 0.465 ± 0.005 * | 49.46 ± 0.50 * | 0.104 ± 0.005 * | 89.33 ± 0.57 * | |
Data of six independent experiments were expressed as mean ± SD. * p < 0.001 vs. control group.
Strophalloside inhibition of SGC-7901 cell migration and invasion.
| Groups | Dose (nM/mL) | Migration | Invasion | ||
|---|---|---|---|---|---|
| Cell Number | Inhibition (%) | Cell Number | Inhibition (%) | ||
| Control | 0.0 | 153.1 ± 8.74 | 00.00 ± 00.00 | 140.8 ± 7.66 | 00.00 ± 00.00 |
| Strophalloside | 0.12 | 127.4 ± 6.52 * | 16.79 ± 7.42 * | 108.0 ± 5.47 * | 23.30 ± 5.30 * |
| 0.24 | 76.7 ± 7.31 * | 49.90 ± 6.31 * | 64.2 ± 6.06 * | 54.40 ± 4.29 * | |
| 0.47 | 49.3 ± 6.47 * | 67.80 ± 8.47 * | 41.2 ± 5.97 * | 70.74 ± 4.24 * | |
| 0.93 | 30.7 ± 7.54 * | 79.95 ± 5.75 * | 22.4 ± 4.77 * | 84.10 ± 3.39 * | |
Data of three independent experiments were expressed as mean ± SE. * p < 0.01 vs. control group.
Figure 2Representative images of cell migration and invasion in control and strophalloside-treated SGC-7901 cells detected by Transwell assays. (a) Migration in the control group; (b) Migration in the strophalloside-treated group (0.47 nM/mL); (c) Invasion in the control group; (d) Invasion in the strophalloside-treated group (0.47 nM/mL).
Figure 3Induction of SGC-7901 cell death in vitro. (a) SGC-7901 cells were treated with 0.93 nM/mL) of strophalloside for 24 h and stained with Hoechst 33258. The apoptotic cells are indicated with arrows. Normal nuclear morphology is observed in untreated cells (control). In contrast, small, fragmented, and condensed nuclei with typical apoptotic morphology were observed in treated cells; (b) The percentage of apoptotic SGC-7901 cells was calculated in 10 hpf by Hoechst 33258 staining; (c) The characteristic images of flow cytometry analysis. SGC-7901 cells were treated with strophalloside (0.24, 0.47, 0.93 nM/mL) for 24 h and stained with FITC-conjugated annexin-V and propidium iodide (PI); (d) The percentage of apoptotic SGC-7901 cells was calculated in triplicate by flow cytometry analysis. * p < 0.001.
Figure 4Inhibition of tumor growth and induction of SGC-7901 cell apoptosis in vivo. SGC-7901 tumor model was established in BALB/c nude mice and injected intravenously with strophalloside (Strop) or DMSO (Control) once every 4 days. On day 18 after tumor cell inoculation, the tumor masses were isolated. (a) The morphology of the tumor masses from the strophalloside-treated mice (upper) and control mice (lower); (b) The tumor volumes; (c) The tumor weights; (d) The percentage of the apoptotic cells calculated from (e); (e) The tumor masses from the strophalloside-treated and the control were sectioned and stained with In Situ Cell Death Detection Kit (fluorescein, Roche). * p < 0.001.
Figure 5Changes of the mitochondrial transmembrane potential and caspase activation by mitochondrial Cyt c. (a) The mitochondrial transmembrane potential was tested using JC-1 fluorescent staining of SGC-7901 cells treated with different concentrations of strophalloside (Strop); (b) The characteristic images of flow cytometry analysis of the red (aggregate) and the green (monomer); (c) The ratio of JC-1 aggregates and monomers were calculated in triplicates by flow cytometry analysis; (d) Strophalloside treatment induced mitochondrial Cyt c released into cytoplasm; (e) Mitochondrion-pathway-related caspase-3 and caspase-9 were activated from procaspases into cleaved states, which were detected by western blotting analysis. The results of (d, e) showed that Cyt c was released from chondriosome and activation of capase-3 and capase-9. * p < 0.05 and ** p < 0.001.